Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727802 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 study, sponsored by Toray Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03727802 is a Phase 1 study that has completed, run by Toray Industries. The registered enrollment target is 34 participants.
The verdict
NCT03727802, a Phase 1 study, has completed, sponsored by Toray Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG TRK-250
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03727802
The ClinicalTrials.gov registry entry for NCT03727802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Toray Industries, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03727802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03727802 about?
NCT03727802 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis". TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primar...
What is the current status of trial NCT03727802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2018-11-28. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03727802?
The interventions under investigation include: Placebo (DRUG), TRK-250 (DRUG).
Who is sponsoring clinical trial NCT03727802?
This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.